$2.23
9.55% today
Nasdaq, Aug 12, 10:04 pm CET
ISIN
US88875G1013
Symbol
TLSA

Tiziana Life Sciences PLC Sponsored ADR Stock price

$2.23
+0.75 50.34% 1M
+1.48 197.46% 6M
+1.53 219.59% YTD
+0.78 53.45% 1Y
+1.55 232.04% 3Y
-2.23 50.11% 5Y
+0.58 35.04% 10Y
+0.58 35.04% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.24 9.55%
ISIN
US88875G1013
Symbol
TLSA
Industry

Key metrics

Basic
Market capitalization
$274.2m
Enterprise Value
$270.6m
Net debt
positive
Cash
$3.7m
Shares outstanding
111.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
69.6
Financial Health
Equity Ratio
34.9%
Return on Equity
-
ROCE
-401.9%
ROIC
-568.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-15.7m | -
EBIT
$-15.8m | $-47.9m
Net Income
$-11.9m | $-15.9m
Free Cash Flow
$-1.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
12.4% | -
EBIT
12.2% | -
Net Income
33.0% | -
Free Cash Flow
90.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
0.7%
Employees
9
Rev per Employee
-
Show more

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 5.23 5.23
36% 36%
-
-16 -16
12% 12%
-
- Depreciation and Amortization 0.12 0.12
20% 20%
-
EBIT (Operating Income) EBIT -16 -16
12% 12%
-
Net Profit -12 -12
33% 33%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Positive
Proactive Investors
one day ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the US Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). The Phase 2a study is a six-month, open-label clinical trial designed to evaluate the effects of intranasal foralumab on microglial activa...
Neutral
GlobeNewsWire
one day ago
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its P...
Positive
Proactive Investors
22 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer's disease showed promising results in a patient, helping reduce brain inflammation and possibly aiding in the removal of harmful protein buildup linked to the disease. The company's lead drug, intranasal foralumab, is a fully human antibody designed to regulate the immune system.
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Mr. Elrifi
Employees 9
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today